admin – Page 3010 – Get News Story

2025 Changchun International Optoelectronic Expo·Light Conference Opens

On 10 June 2025, the opening ceremony of the 2025 Changchun International Optoelectronic Expo · Light Conference was held. Huang Qiang, Secretary of the Jilin Provincial Party Committee, attended and declared the event open. Hu Yuting, Deputy Secretary of the Jilin Provincial Party Committee and Governor of Jilin Province, delivered a speech.

The 2025 Changchun International Optoelectronic Expo · Light Conference has attracted over 850 enterprises from 7 countries, including 14 Fortune Global 500 companies, 20 China Fortune 500 companies, and 51 listed companies. Huang Qiang and Hu Yuting, accompanied by key guests, toured the exhibition halls. They visited the booths of companies such as Hikvision, BOE, and China Electronics Technology Group Corporation (CETC), gaining detailed insights into industry development. Huang Qiang stated that China’s optical industry first took root in Jilin, making the province the foundational birthplace of China’s optoelectronic information industry. He expressed hope that exhibiting enterprises would strengthen cooperation with Jilin, increase investment and strategic presence, encourage supporting enterprises to follow suit, and help build a stronger, larger optoelectronic information industrial cluster in Jilin. He urged all localities and relevant departments to provide support commensurate with the scale of enterprises, thoroughly understand the development plans of major central state-owned enterprises and leading private firms, identify synergies for mutually beneficial cooperation during the 15th Five-Year Plan period, jointly plan and implement major projects, create more application scenarios, and better lead industrial development. At the booths of the Changchun Institute of Optics, Fine Mechanics and Physics (CIOMP) of the Chinese Academy of Sciences and Huawei Technologies Co., Ltd., Huang Qiang noted CIOMP’s strong scientific research capabilities and Huawei’s extensive market experience. He emphasized that Jilin would mobilize all provincial resources to support fruitful cooperation between the two, ensuring more projects take root in Jilin. Huang Qiang and Hu Yuting also visited exhibition areas of universities, research institutes, and the talent exchange zone, learning about the latest technological advancements and encouraging more outstanding talents and R&D teams to come to Jilin for innovation and entrepreneurship.

In his speech, Hu Yuting highlighted Jilin’s status as the cradle of China’s optical industry and its solid foundation and vast potential in the optoelectronic information sector. He noted that this year’s expo, themed “Optoelectronics Leads the Way, High-Quality Powers the Future,” aims to create a global optoelectronic event integrating technology exchange, industrial cooperation, talent aggregation, and brand building. It will significantly boost the growth of Jilin’s optoelectronic information industry and inject new momentum into Jilin’s revitalization and breakthroughs. Jilin will focus on its distinctive strengths in “Chips, Optics, Satellites, Vehicles, and Networks”, building six major industrial clusters including optoelectronic materials and displays, striving to create a 100-billion-yuan “Changchun Optics Valley” and an internationally competitive “China Optoelectronics City”. The province will coordinate the integrated development of education, science, technology, talent, and industry, deepen organized efforts in sci-tech innovation, strengthen the role of enterprises as the main drivers of innovation, and establish itself as a source of scientific and technological innovation and a new highland for industrial development in optoelectronics. Hu called on professionals across the optoelectronic field to enhance exchanges and cooperation with Jilin, bringing more technological talents, innovation resources, and major projects to the province. He pledged Jilin’s commitment to creating a first-class innovation ecosystem and business environment to share development opportunities and embrace a bright future together.

The opening ceremony featured a special promotional film for the 2025 Changchun International Optoelectronic Expo. Speeches were delivered by Cao Jianlin, Honorary Editor-in-Chief of “Light” and Chairman of the Changchun International Optoelectronic Expo Organizing Committee; Li Deren, recipient of China’s State Preeminent Science and Technology Award and Academician of both the Chinese Academy of Sciences and Chinese Academy of Engineering; Sune Svanberg, Academician of the Royal Swedish Academy of Sciences and Royal Swedish Academy of Engineering Sciences; Gu Ying, Academician of the Chinese Academy of Sciences and President of the Chinese Optical Society; and Gu Yunbo, President of Optical Transmission Domain at Huawei Technologies Co., Ltd.

The ceremony was presided by Zhang Enhui, Member of the Standing Committee of the Jilin Provincial Party Committee and Secretary of the Changchun Municipal Party Committee. Attendees included provincial and municipal leaders such as Li Wei, Jin Yuhui, Wang Zhihou, Wang Zilian, and Gao Zhiguo; Liu Yigong, General Manager of China FAW Group; representatives of domestic and international academicians and experts; heads of relevant provincial departments, renowned domestic and international enterprises, universities, research institutes, and industry associations (societies); Wang Sen, daughter of the late Academician Wang Daheng; and Lu Changqin, wife of Comrade Jiang Zhuying.

(Reporters: Huang Lu, Wang Baozeng)

Media Contact
Company Name: 2025 Changchun International Optoelectronic Expo·Light Conference
Contact Person: Wang Shuang
Email: Send Email
Country: China
Website: https://ccioe.com.cn/

Chronic Spontaneous Urticaria Market Size in the 7MM was ~USD 2000 million in 2023, is expected to grow a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Chronic Venous Insufficiency Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Chronic Venous Insufficiency, historical and forecasted epidemiology as well as the Chronic Venous Insufficiency market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Chronic Venous Insufficiency Market Share @ Chronic Venous Insufficiency Market Outlook

Key Takeaways from the Chronic Venous Insufficiency Market Report

In the 7MM, the US accounted for the highest number of Chronic Venous Insufficiency Prevalent Cases with nearly 6.2 million in 2020.
In the 7MM, the total Chronic Venous Insufficiency Prevalent Cases were 463 million in 2020,
Among EU4 and the UK, Germany accounted for the highest number of cases of Chronic Venous Insufficiency, followed by UK, whereas Spain occupied the bottom of the ladder.
According to DelveInsight’s epidemiology model for CVD, the C1 stage had the highest diagnosed prevalence in the United States.
The leading Chronic Venous Insufficiency Companies such as Verigraft AB, enVVeno Medical Corporation, Theraclion and others.
Promising Chronic Venous Insufficiency Pipeline Therapies such as Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus and others.

Stay ahead in the Chronic Venous Insufficiency Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Venous Insufficiency Treatment Market

Chronic Venous Insufficiency Epidemiology Segmentation in the 7MM

For the epidemiology forecast model of CVI, the total Chronic Venous Insufficiency prevalence was first calculated for the adult population. Since not all patients with CVD are diagnosed, using the disease diagnosis rate, the number of diagnosed prevalent cases of CVD was determined. From this segmentation, the diagnosed prevalent cases specific to CVI were derived by aggregating the total cases within stages C3–C6 of the CEAP classification. Subsequently, these CVI cases were further segmented to ascertain the number of cases specific to each gender. in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Download the report to understand which factors are driving Chronic Venous Insufficiency Epidemiology trends @ Chronic Venous Insufficiency Prevalence

Chronic Venous Insufficiency Marketed Drugs

Venclose System: BD

The Venclose System consists of two main components: 1) Maven Catheter with integrated cable connector and, 2) digiRF Generator which delivers radiofrequency (RF) energy to the Maven catheter. The Maven catheter is a sterile single-use disposable medical device for endovenous radiofrequency ablation. The primary components of the catheter include the shaft, handle and integrated connector cable. The catheter shaft is 6 French (6F = 2.0 mm in diameter) in profile, with an insertable length of 40 cm and a 0.5 cm heating coil. The catheter is energized by the digiRF Generator which is a multi-voltage energy delivery system with touchscreen control that automatically sets the non-adjustable treatment parameters for the catheter. The Venclose Maven System (digiRF Generator and Maven Catheter) uses resistive radiofrequency ablation (via energy delivered to heat the wall of an incompetent vein) with temperature-controlled RF energy, and an already widely accepted procedure to cause irreversible luminal occlusion. This is followed by fibrosis and ultimately resorption of the vein. The Venclose Maven System (digiRF Generator and Maven Catheter) supports an optional foot pedal.

Chronic Venous Insufficiency Emerging Drugs

P-TEV: Verigraft AB

P-TEV (Personalized Tissue-Engineered Veins) is an advanced therapy medicinal product (ATMP) being developed by Verigraft as an alternative to autologous or synthetic vascular grafts used in reconstructive vein surgery. The P-TEV drug substance consists of an extracellular matrix (ECM) scaffold in the form of a decellularized (DC) allogeneic vein scaffold which is populated with autologous components from the patient’s own peripheral whole blood (PWB) in an ATMP manufacturing process performed under GMP. As the allogeneic immunogenic material has been removed from the donated vein segment by DC and as the perfusion uses autologous PWB, no immunosuppression is required.

To learn more about Chronic Venous Insufficiency Treatment guidelines, visit @ Chronic Venous Insufficiency Clinical Trials Assessment

Chronic Venous Insufficiency Companies

Verigraft AB, enVVeno Medical Corporation, Theraclion and others.

Chronic Venous Insufficiency Market Outlook

In the Chronic Venous Insufficiency pipeline among the emerging candidates, SONOVEIN, which is a robotic solution for non-invasive echotherapy treatment using high-intensity focused ultrasound (HIFU) technology. It operates independently without the need for additional accessories such as guide wires, puncture kits, or catheters. The device is being evaluated in a VEINRESET study, which is now transitioning into a 12-month follow-up period, with results projected for release by 2025. The company plans to file the market approval application with the FDA once the study report is available in the second half of 2025.

Learn more about the FDA-approved drugs for Chronic Venous Insufficiency @ Drugs for Chronic Venous Insufficiency Treatment

Scope of the Chronic Venous Insufficiency Market Report

Coverage- 7MM
Study Period- 2020-2034
Chronic Venous Insufficiency Companies- Verigraft AB, enVVeno Medical Corporation, Theraclion and others.
Chronic Venous Insufficiency Pipeline Therapies- Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus and others.
Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency Market Drivers and Barriers
Chronic Venous Insufficiency Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Chronic Venous Insufficiency Market Report Introduction

3. Chronic Venous Insufficiency Market Overview at a Glance

4. Chronic Venous Insufficiency Epidemiology and Market Methodology

5. Chronic Venous Insufficiency Executive Summary

6. Key Events

7. Chronic Venous Insufficiency Market Disease Background and Overview

8. Patient Journey

9. Chronic Venous Insufficiency Epidemiology and Patient Population

10. Chronic Venous Insufficiency Marketed Drugs

11. Chronic Venous Insufficiency Emerging Drugs

12. Chronic Venous Insufficiency Emerging Devices

13. Chronic Venous Insufficiency: Market Analysis

14. Key Opinion Leaders’ Views

15. Chronic Venous Insufficiency SWOT Analysis

16. Chronic Venous Insufficiency Unmet Needs

17. Chronic Venous Insufficiency Market Drivers

18. Chronic Venous Insufficiency Market Barriers

19. Chronic Venous Insufficiency Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-venous-insufficiency-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Market Size in the 7MM was ~USD 2000 million in 2023, is expected to grow a significant CAGR by 2034, estimates DelveInsight

CAR-T Cell Therapy for ALL Market Size in the 7MM was ~USD 200 million in 2023, and is further expected to increase by 2034, estimates DelveInsight

DelveInsight’s “CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Acute Lymphoblastic Leukemia, historical and forecasted epidemiology as well as the CAR-T Cell Therapy for Acute Lymphoblastic Leukemia market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Discover which therapies are expected to grab the CAR T-Cell Therapy for ALL Market Share @ CAR T-Cell Therapy for ALL Market Outlook

Key Takeaways from the CAR T-Cell Therapy for ALL Market Report

In June 2025, Peter MacCallum Cancer Centre, Australia conducteda Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
In June 2025, M.D. Anderson Cancer Center conducted a Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia.
Among the 7MM, the US accounted for the highest Acute Lymphoblastic Leukemia incidence.
The total incident cases of Acute Lymphoblastic Leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period.
Amongst EU4 and the UK, Germany accounted for the highest number of incident cases of Acute Lymphoblastic Leukemia, while Spain accounted for the lowest number of cases.
Among the gender-specific cases, males accounted for nearly 3,800 cases, while females accounted for 3,000 in the US in 2023.
Among the type-specific cases of Acute Lymphoblastic Leukemia, the incident cases of B-Acute Lymphoblastic Leukemia accounted for nearly 85%, while that of T-Acute Lymphoblastic Leukemia accounted for nearly 15% in the US.
The leading CAR T-Cell Therapy for ALL Companies such as Autolus Therapeutics, Cellectis, Wugen, Servier, Allogene, Precision Biosciences and others.
Promising CAR T-Cell Therapy for ALL Pipeline Therapies such as Cevostamab, Epcoritamab, BCMA CAR-T cells, Talquetamab, CTO1681 10 μg, Bortezomib, Dexamethasone, Lenalidomide and others.

Stay ahead in the CAR T-Cell Therapy for ALL Therapeutics Market with DelveInsight’s Strategic Report @ CAR T-Cell Therapy for ALL Treatment Market

CAR T-Cell Therapy for ALL Epidemiology Segmentation in the 7MM

Total CAR T-Cell Therapy for ALL Incident Cases
CAR T-Cell Therapy for ALL Gender-specific cases
CAR T-Cell Therapy for ALL Age-specific cases
CAR T-Cell Therapy for ALL Subtype-specific cases
CAR T-Cell Therapy for ALL Genetic-mutation specific cases
Total CAR T-Cell Therapy for ALL treated cases

Download the report to understand which factors are driving CAR T-Cell Therapy for ALL Epidemiology trends @ CAR T-Cell Therapy for ALL Prevalence

Marketed CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Drugs

TECARTUS (brexucabtagene autoleucel): Gilead Sciences

TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, which binds to CD19-expressing cancer cells and normal B cells. Studies demonstrated that following anti-CD19 CAR-T cell engagement with CD19-expressing target cells, the CD28 and CD3-zeta costimulatory domains activate downstream signaling cascades that lead to T cell activation, proliferation, acquisition of effector functions, and secretion of inflammatory cytokines and chemokines. This sequence of events leads to the killing of CD19-expressing cells. In October 2021, the US FDA approved TECARTUS for adult patients with R/R B-Acute Lymphoblastic Leukemia. It was approved by the EC in September 2022.

KYMRIAH (tisagenlecleucel): Novartis

KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy that involves reprogramming a patient’s T cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells. The CAR is comprised of a murine single-chain antibody fragment that recognizes CD19 and is fused to intracellular signaling domains. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, target cell elimination, and persistence of the KYMRIAH cells. In August 2017, the US FDA approved KYMRIAH for the treatment of patients up to age 25 years with R/R B-Acute Lymphoblastic Leukemia. It was approved by the EC in August 2018, and by the MHLW in March 2019.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs

Obecabtagene autoleucel (obe-cel): Autolus Therapeutics

Obe-cel is an autologous CD19 CAR-T cell therapy with a unique CD19 CAR. The CAR is designed to have a fast-off kinetic, which mimics physiological T-cell receptor interactions. In March 2022, obe-cel was granted Orphan Medical Product Designation by the EMA for the treatment of Acute Lymphoblastic Leukemia, having previously received ODD by the US FDA for B-Acute Lymphoblastic Leukemia. In April 2022, the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obe-cel for the treatment of adult B-Acute Lymphoblastic Leukemia. Obe-cel also received PRIME designation from the EMA and Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare Products Regulatory Agency (MHRA), UK.

UCART22: Cellectis

UCART22 is an allogeneic-engineered T-cell product candidate designed for the treatment of CD22-expressing hematologic malignancies and is currently being developed for the treatment of B-Acute Lymphoblastic Leukemia. Currently, the company is evaluating the drug in Phase I/II B Acute Lymphoblastic Leukemia I-01 Study in patients with R/R Acute Lymphoblastic Leukemia. As of the December 2021 report, the company is enrolling patients in the third dose level of the B Acute Lymphoblastic Leukemia I-01 Study with a fludarabine cyclophosphamide alemtuzumab lymphodepletion regimen.

To learn more about CAR T-Cell Therapy for ALL Treatment guidelines, visit @ CAR T-Cell Therapy for ALL Clinical Trials Assessment

CAR T-Cell Therapy for ALL Companies

Autolus Therapeutics, Cellectis, Wugen, Servier, Allogene, Precision Biosciences and others.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Market Outlook

Traditional cytotoxic chemotherapy-containing regimens have been the backbone of treatment for adults with Acute Lymphoblastic Leukemia for decades. Common complications of traditional chemotherapy can be fatal and include infection, bleeding, thrombosis, neuropathy, osteonecrosis, and the development of secondary cancers, including AML and MDS.

CAR T-Cell Therapy for ALL Drugs Market Insights

Since the first successful report of CAR-T cell therapy for pediatric Acute Lymphoblastic Leukemia more than a decade ago, the field has exploded with new constructs and targets, insights into CAR T-cell persistence, and novel antigen escape mechanisms; first came KYMRIAH (tisagenlecleucel, or tisa-cel, Novartis) for pediatric and young adult patients who had received at least two prior lines of therapy, followed by TECARTUS (brexucabtagene autoleucel, or brexu-cel, Kite) for adults following first relapse. It is anticipated that CAR-T cells will bring out the next big leap forward in leukemia immunotherapy.

Learn more about the FDA-approved drugs for CAR T-Cell Therapy for ALL @ Drugs for CAR T-Cell Therapy for ALL Treatment

Scope of the CAR T-Cell Therapy for ALL Market Report

Coverage- 7MM
Study Period- 2020-2034
CAR T-Cell Therapy for ALL Companies- Autolus Therapeutics, Cellectis, Wugen, Servier, Allogene, Precision Biosciences, and others.
CAR T-Cell Therapy for ALL Pipeline Therapies- Cevostamab, Epcoritamab, BCMA CAR-T cells, Talquetamab, CTO1681 10 μg, Bortezomib, Dexamethasone, Lenalidomide, and others.
CAR T-Cell Therapy for ALL Market Dynamics: CAR T-Cell Therapy for ALL Market Drivers and Barriers
CAR T-Cell Therapy for ALL Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1 KEY INSIGHTS

2 REPORT INTRODUCTION

3 EXECUTIVE SUMMARY OF CAR-T IN Acute Lymphoblastic Leukemia

4 KEY EVENTS

5 EPIDEMIOLOGY AND MARKET METHODOLOGY

6 CAR-T IN Acute Lymphoblastic Leukemia MARKET OVERVIEW AT A GLANCE

7 DISEASE BACKGROUND AND OVERVIEW

8 CURRENT TREATMENT PRACTICES: Acute Lymphoblastic Leukemia

9 EPIDEMIOLOGY AND PATIENT POPULATION OF 7MM

10 PATIENT JOURNEY

10.1 TYPICAL CAR T-CELL PATIENT JOURNEY

11 MARKETED DRUGS

12 EMERGING DRUGS

13 CAR-T IN Acute Lymphoblastic Leukemia: THE 7MM ANALYSIS

14 UNMET NEEDS

15 SWOT ANALYSIS

16 KOL VIEWS

17 MARKET ACCESS AND REIMBURSEMENT

18 APPENDIX

19 DELVEINSIGHT CAPABILITIES

20 DISCLAIMER

21 ABOUT DELVEINSIGHT

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Cell Therapy for ALL Market Size in the 7MM was ~USD 200 million in 2023, and is further expected to increase by 2034, estimates DelveInsight

Entrepreneur Jesse Vierstra Featured in Exclusive Online Interview Highlighting Faith, Innovation, and Community Impact

Jesse Vierstra, founder and owner of Iron Oaks Custom Homes, was recently featured in an in-depth online interview spotlighting his journey from a family-run dairy farm in Twin Falls to becoming a respected builder, entrepreneur, and community leader. The candid Q&A dives into Jesse’s philosophy on leadership, faith-driven productivity, and the lessons he’s learned while building over 50 custom homes and multiple successful businesses.

In the interview, Jesse shares insights into how he starts each day with intention, balances family life and entrepreneurship, and brings innovation—like solar energy integration in agriculture—into the construction world. He also discusses his commitment to mentorship, philanthropy, and community service, including founding the Ryan Franklin Memorial Golf Tournament.

Jesse’s story resonates as a blueprint for purposeful growth, rooted in values, resilience, and service. His book, Under the Red Oak Tree, was also highlighted, offering readers a personal glimpse into the principles that guide both his business and personal life.

The feature sheds light on Jesse’s unique leadership style, which blends hands-on involvement with long-term vision. He emphasizes the power of local impact, relationship-building, and giving back to the community as key drivers of sustainable success. As an avid golfer, skier, and man of faith, Jesse’s well-rounded approach to life and business offers inspiration to aspiring entrepreneurs and seasoned professionals alike.

To read the full interview, visit the website here.

Media Contact
Contact Person: Jesse Vierstra
Email: Send Email
City: Twin Falls
State: Idaho
Country: United States
Website: https://www.jessevierstraconstruction.com/

Bridal Bargains: Missacc Delivers Custom Fit Dresses at Affordable Prices

The global wedding dress market is experiencing unprecedented growth, with industry analysts projecting the market to reach USD 24.34 billion by 2033, driven by modern brides seeking personalized and inclusive fashion solutions. As the growing desire for personalized bridal gowns becomes a major driver of the bridal wear market, couples are increasingly turning away from traditional one size fits all approaches in favor of customized experiences that reflect their unique style and budget constraints.

Enter Missacc, established in 2017 as an online boutique specializing in wedding and formal dresses, which has emerged as a transformative force in the custom bridalwear industry. The brand has revolutionized how modern brides approach wedding fashion by offering size inclusive formal dresses at affordable prices with curve flattering fits, free custom sizing, and easy returns. With a commitment to making luxury and customization accessible to all, Missacc addresses the growing demand for personalized bridal solutions without the traditional premium pricing that has historically excluded many couples from their dream wedding attire.

The company’s innovative approach centers on democratizing custom bridalwear through factory direct operations and advanced sizing technology. Known for its in house wedding dress factory and expert design team, Missacc combines elegance, quality, and affordability to offer a wide range of gowns for weddings, proms, and other milestone celebrations. This vertical integration allows the brand to maintain exceptional quality standards while offering competitive pricing that starts at just $99 for custom fitted dresses.

missacc handmade custom wedding dresses

Key Features Driving Missacc’s Market Leadership

Budget Friendly Customization: The brand’s revolutionary pricing model delivers custom fitted dresses starting at $99, proving that personalization doesn’t require premium pricing. This approach directly addresses the financial pressures many couples face when planning their special day.

Size Inclusive Excellence: Missacc’s fully customizable sizing system supports all body types, with free custom sizing and a 14 day return policy ensuring every bride achieves the perfect fit regardless of traditional sizing constraints.

Rapid Production Timeline: Standard orders ship within 10 to15 business days, with expedited rush options available in 5 to 7 business days, addressing the time sensitive nature of wedding planning.

Factory Direct Advantages: The company’s proprietary manufacturing line maintains quality control while eliminating intermediary markups, passing savings directly to customers.

Global Accessibility: International shipping capabilities and comprehensive customer service support ensure brides worldwide can access Missacc’s custom solutions.

“The modern bride deserves a dress that fits beautifully—both physically and financially,” said Leon, CEO at Missacc. “Missacc is proud to offer custom designs that don’t break the bank, proving that exceptional quality and personalization can be accessible to every bride regardless of budget or body type.”

Missacc Sets New Standards in Bridalwear with Sustainable, Custom Fit Designs and a Digital First Customer Experience

The brand’s customer centric approach extends beyond pricing to encompass a comprehensive made to order model that minimizes waste while maximizing personalization options. This sustainable approach resonates with environmentally conscious couples who value both style and responsibility. The company’s 2025 collection features timeless A line, mermaid, and bridal gowns crafted in lace, satin, and tulle, blending current fashion trends with timeless elegance.

Missacc’s commitment to innovation has resulted in significant operational improvements, including streamlined lead times, enhanced design tools, and comprehensive international sizing guides that accommodate global customers. The brand’s focus on customer satisfaction has generated substantial social proof, with 4523 customer reviews at trustpilot and received 4.3 stars.

With 24/7 customer support and comprehensive service offerings, Missacc has positioned itself as more than a dress retailer—the brand serves as a complete solution partner for brides navigating the complex world of wedding fashion. The company’s holistic approach addresses common pain points in traditional bridal shopping, including limited size options, lengthy wait times, inflexible return policies, and prohibitive pricing structures.

As the wedding industry continues evolving toward greater inclusivity and accessibility, Missacc’s model represents a significant shift in how custom bridalwear can be conceived, produced, and delivered. The brand’s success demonstrates that quality, customization, and affordability need not be mutually exclusive, setting new standards for customer expectations and industry practices.

Brides and fashion enthusiasts can browse Missacc’s complete collection and begin their custom dress journey at www.missacc.com, where personalized consultations and comprehensive sizing support ensure every customer finds their perfect match.

About Missacc

Missacc, established in 2017, is an online boutique specializing in wedding and formal dresses, devoted to providing women with an endless variety of timeless gowns and dresses that make their formal and special occasions unforgettable. The brand’s mission centers on democratizing access to custom fitted, high quality bridalwear through innovative manufacturing processes, inclusive sizing options, and transparent pricing structures. With a comprehensive catalog spanning wedding gowns, bridesmaid dresses, mother of the bride attire, and formal occasion wear, Missacc serves as a complete solution provider for wedding fashion needs. The company’s commitment to excellence extends through every aspect of the customer experience, from initial consultation through final delivery, ensuring every bride receives personalized attention and exceptional value.

Media Contact
Company Name: Missacc Inc.
Contact Person: Lilian Fu
Email: Send Email
Phone: +1562-206-9998
City: Los Angeles
Country: United States
Website: https://www.missacc.com

Missacc Gains Momentum as a Trusted Destination for Custom Fit Formal Dresses in 2025

With extended sizing, personalized fit options, and fashion forward styles, Missacc redefines the formal dress experience for Gen Z shoppers

The formal wear industry has long struggled with inclusivity challenges, leaving many young shoppers frustrated with limited sizing options, poor fit quality, and cookie cutter designs that fail to reflect individual style preferences. As Generation Z increasingly demands authenticity, sustainability, and personalization in their fashion choices, traditional formal dress retailers have been slow to adapt to these evolving expectations. The disconnect between what young consumers want and what the market offers has created a significant opportunity for innovative brands willing to challenge conventional approaches to formal wear.

Against this backdrop of industry transformation, Missacc has emerged as a pioneering force in the formal dress market. It is now the go-to destination for custom-fit formal dresses that celebrate individuality and inclusivity. Founded on the principle that every person deserves to feel confident and beautiful in perfectly fitted formal wear, Missacc has revolutionized the special occasion dresses shopping experience by combining cutting edge customization technology with trend forward design aesthetics that resonate with modern consumers.

The brand’s comprehensive approach to formal wear extends far beyond traditional retail models, offering personalized consultation services, extensive sizing options, and design flexibility that allows customers to create truly unique pieces for their special occasions. Missacc’s commitment to inclusivity is evident in its extended size range, accommodating bodies of all shapes and proportions through innovative design techniques and custom manufacturing processes that prioritize fit and comfort without compromising style.

missacc customized wedding dresses

Missacc’s Revolutionary Differentiation Strategy

Missacc has distinguished itself in the competitive formal wear market through its innovative approach to custom sizing that goes far beyond simple alterations. The brand’s design philosophy centers on creating garments from the ground up rather than merely resizing standard pieces, ensuring optimal fit and proportion for each individual customer’s unique body type and style preferences.

The company’s dresses design team draws inspiration from diverse sources, including high fashion runways and trending social media platforms like TikTok, creating a unique blend of sophisticated elegance and contemporary relevance that appeals specifically to Gen Z aesthetics. This approach ensures that Missacc’s offerings remain current with rapidly evolving fashion trends while maintaining the timeless elegance expected in formal wear.

Standout Features Driving Market Success

Missacc’s product portfolio showcases trend forward silhouettes that have become signature elements of the brand’s identity. The collection features sophisticated mermaid cuts that enhance natural curves, flattering A line designs that suit virtually every body type, striking asymmetrical styles that add modern edge, and versatile two piece options that allow for creative styling combinations.

The brand’s color palette has been carefully curated to reflect Gen Z’s distinctive taste preferences, featuring lustrous metallics that photograph beautifully under various lighting conditions, rich jewel tones that add depth and sophistication, and soft pastels that provide romantic elegance for those preferring subtler aesthetics.

Perhaps most remarkably, Missacc has achieved luxury quality construction and materials while maintaining accessible pricing, with most custom dresses available for under $150. This pricing strategy has democratized access to high quality formal wear, making custom fit options available to customers who previously couldn’t afford personalized formal wear services.

Demonstrable Market Growth and Recognition

The brand’s success is reflected in impressive performance metrics across multiple channels. Missacc has experienced substantial online traffic growth year over year, with website visits increasing significantly as word of mouth recommendations and positive customer experiences drive organic growth. Customer satisfaction ratings consistently exceed industry standards, with particularly high marks for fit quality, design uniqueness, and customer service excellence.

The company’s high return customer rate demonstrates strong brand loyalty, with many customers returning for additional formal occasions and recommending the brand to friends and family members. Social media engagement has surged, with numerous influencer collaborations and organic customer posts showcasing Missacc designs at special events across the country, creating authentic brand advocacy that resonates with target demographics.

Future Innovation and Growth Initiatives

Looking ahead, Missacc continues to invest in expanding its market leadership through strategic initiatives designed to further enhance the customer experience and broaden accessibility.

Continued investment in plus size and adaptive fashion innovation remains a priority, with research and development efforts focused on creating even more inclusive sizing options and design features that accommodate diverse accessibility needs. These initiatives reflect Missacc’s commitment to ensuring that formal wear truly serves all members of the community.

Building Confidence and Community

The impact of Missacc’s approach extends far beyond individual transactions, creating meaningful experiences that build lasting confidence and foster community connections among customers. The brand’s emphasis on personalization and individual expression has resonated particularly strongly with Gen Z consumers who value authenticity and self expression in their fashion choices.

Customer testimonials consistently highlight not just satisfaction with the physical product, but transformation experiences that boost confidence and create positive memories associated with important life milestones. This emotional connection has become a defining characteristic of the Missacc brand experience, setting it apart from traditional retail approaches to formal wear.

Missacc isn’t just creating dresses—the company is building confidence, fostering community connections, and establishing a new standard for what formal wear should feel like in 2025 and beyond. Through its commitment to inclusivity, personalization, and trend forward design, Missacc has positioned itself as more than a fashion retailer, becoming a trusted partner in helping young people celebrate their most important moments with confidence and style.

About Missacc

Missacc is a leading destination for custom fit formal wear, specializing in prom dresses, wedding gowns, evening wear, and special occasion attire. The brand’s mission centers on democratizing access to high quality, perfectly fitted formal wear through innovative customization services and inclusive design practices. Missacc serves customers nationwide through its online platform, offering personalized consultation services and custom manufacturing that celebrates individual style and body diversity.

Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million in 2023 and is expected to increase a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Biliary Tract Cancer Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology, as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Biliary Tract Cancer Market Share @ Biliary Tract Cancer Market Outlook

Key Takeaways from the Biliary Tract Cancer Market Report

In June 2025, AstraZeneca announced a study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy in participants with BTC after surgical resection with curative intent.
In June 2025, Merck Sharp & Dohme LLC conducted a Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers.
In the 7MM, the United States accounted for the highest Biliary Tract Cancer market size, with nearly 48% of the market share of the Biliary Tract Cancer market as compared to EU4 and the UK and Japan in 2023.
In 2023, among EU4 and the UK, Italy accounted for the largest Biliary Tract Cancer market size, while Spain accounted for the smallest Biliary Tract Cancer market share.
The clinical features of Biliary Tract Cancer depend on the location of the tumor. Patients with extrahepatic tumors usually present with painless jaundice from biliary obstruction, and patients with intrahepatic tumors usually present with pain. Common complaints include pruritus, abdominal pain, malaise, fatigue, pruritus jaundice, and fever.
Biliary tract cancer is usually diagnosed with the clinical examination of the abdomen, using imaging scans, ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and biopsy.
In 2023, Japan accounted for the highest number of total incident cases of Biliary Tract Cancer in the 7MM.
In the United States, Biliary Tract Cancer occurs majorly in the age group of 70–79 years, constituting approximately ~30% of the total age-specific cases of Biliary Tract Cancer.
Among the EU4 and the UK, the mutation-specific cases of Biliary Tract Cancer were highest in TP53 mutations, followed by KRAS mutations in 2023.
The leading Biliary Tract Cancer Companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
Promising Biliary Tract Cancer Pipeline Therapies such as Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.

Stay ahead in the Biliary Tract Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Biliary Tract Cancer Treatment Market

Biliary Tract Cancer Epidemiology Segmentation in the 7MM

Total Biliary Tract Cancer Incident Cases
Biliary Tract Cancer Age-specific Cases
Biliary Tract Cancer Stage-specific Cases
Total Incident Cases of Biliary Tract Cancer by tumor location in the 7MM
Biliary Tract Cancer Mutation-specific Cases
Biliary Tract Cancer Treated Cases

Download the report to understand which factors are driving Biliary Tract Cancer Epidemiology trends @ Biliary Tract Cancer Prevalence

Biliary Tract Cancer Marketed Drugs

PEMAZYRE (pemigatinib): Incyte

PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMFINZI (durvalumab): AstraZeneca

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with gemcitabine and cisplatin as treatment of adult patients with locally advanced or metastatic Biliary Tract Cancer.The approval for the treatment of adult patients with locally advanced or metastatic by the US FDA was based on the results from the TOPAZ-1 Phase III trial.

Biliary Tract Cancer Emerging Therapies

CTX-009: Compass Therapeutics

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.

Zanidatamab: Jazz Pharmaceuticals/Zymeworks

Zanidatamab is a novel, late-stage oncology asset with the potential to transform the standard of care in multiple HER2-expressing cancers. It has demonstrated compelling data in biliary tract cancers and gastroesophageal adenocarcinoma with the potential to benefit patients across multiple tumor types.A pivotal Phase II clinical trial evaluating zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified Biliary Tract Cancer.

To learn more about Biliary Tract Cancer Treatment guidelines, visit @ Biliary Tract Cancer Clinical Trials Assessment

Biliary Tract Cancer Companies

Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.

Biliary Tract Cancer Market Outlook

Bile duct cancer begins when healthy cells in the bile duct change and grow out of control, forming a mass called a tumor. A tumor can be benign or cancerous. A benign tumor can grow but will not spread. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. Treatment options for the early-stage disease include surgery, followed by adjuvant chemotherapy. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival.

Biliary Tract Cancer Treatment Market

The biliary tract comprises of gallbladder and intra and extrahepatic biliary tree. Bile is directed through these ducts to the second part of duodenum at major duodenal papilla. The epithelium of the biliary tract is lined with cells called cholangiocytes. Carcinoma of the biliary tract arises from the malignant transformation of the epithelium of the bile ducts which is made up of these cholangiocytes, and is categorized on the basis of its anatomical location as; 1) Intrahepatic cholangiocarcinoma 2) Extrahepatic cholangiocarcinoma, which includes; perihilar tumor also known as Klatskin tumor (originating from the epithelium of the bile duct at the junction of right and left hepatic ducts with the cystic duct where it forms the common bile duct) and distal cholangiocarcinoma outspreading to encompass the gallbladder, ampulla of Vater and pancreatic biliary ducts.

Learn more about the FDA-approved drugs for Biliary Tract Cancer @ Drugs for Biliary Tract Cancer Treatment

Scope of the Biliary Tract Cancer Market Report

Coverage- 7MM
Study Period0- 2020-2034
Biliary Tract Cancer Companies- Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
Biliary Tract Cancer Pipeline Therapies- Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.
Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer Market Drivers and Barriers
Biliary Tract Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Biliary Tract Cancer (BTC)

4. Key Events

5. Biliary Tract Cancer Market Overview at a Glance

6. Disease Background and Overview

7. Current Treatment Practices of Biliary Tract Cancer

8. Guidelines: Diagnosis and Treatment

9. Biliary Tract Cancer Epidemiology and Market Forecast Methodology

10. Biliary Tract Cancer Epidemiology and Patient Population

11. Biliary Tract Cancer Patient Journey

12. Marketed Biliary Tract Cancer Therapies

13. Emerging Biliary Tract Cancer Therapies

14. Biliary Tract Cancer (BTC) Market Analysis

15. Biliary Tract Cancer Unmet Needs

16. Biliary Tract Cancer SWOT Analysis

17. KOL Views

18. Biliary Tract Cancer Market Access and Reimbursement

19. Biliary Tract Cancer Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million in 2023 and is expected to increase a significant CAGR by 2034, estimates DelveInsight

Aplastic Anemia Treatment Market Size in the 7MM was ~USD 270 million in 2023 and is further expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Aplastic Anemia Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology, as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Aplastic Anemia Market Share @ Aplastic Anemia Market Outlook

Key Takeaways from the Aplastic Anemia Market Report

In May 2025, Emory University announced a study will enroll 30 pediatric patients with serious non-malignant hematologic diseases (NMHD) undergoing URD HSCT. The trial will include patients with 7/8 donors and those with 8/8 (matched) donors. All participants will receive 8 doses of abatacept. Recruitment is expected to last for about 2 years and participants will be followed for up to 3 years.
In May 2025, Medical College of Wisconsin conducted a study is a prospective, multicenter Phase II study of hematopoietic stem cell transplantation for previously untreated patients with severe aplastic anemia (SAA). Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. Patients with aplastic anemia have low white blood cells (cells which fight infection), low red blood cells (cells that carry oxygen throughout the body), and low platelets (cells that help form clots and prevent bleeding). Treatments for SAA seeks to repair this abnormal immune system attack and allow the bone marrow to make the normal amount of blood cells. This can be done with a bone marrow transplant or with medications to suppress the immune system.
In May 2025, Fred Hutchinson Cancer Center organized phase II trial tests how well a ruxolitinib-based graft versus host disease (GVHD) prevention (prophylaxis) regimen works before, during, and after bone marrow/stem cell transplantation (hematopoietic cell transplantation [HCT]) in patients with acquired aplastic anemia. Acquired aplastic anemia (AA) is a condition in which the bone marrow is unable to produce blood cells.
The total Aplastic Anemia Treatment Market Size was found to be ~USD 270 million in 2023 in the 7MM, which is further expected to increase by 2034.
Among the 7MM, Japan accounts for the second highest total aplastic anemia drugs market. The Aplastic Anemia Treatment Market Size in Japan has been assessed to be ~USD 35 million in 2023, expected to increase during the forcast period.
During the forecast period, Aplastic Anemia pipeline candidates such as Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline) are expected to drive the rise in Aplastic anemia market size.
Among EU4 and the UK, Germany accounts for the highest Aplastic Anemia Treatment Market Size with ~USD 14 million in 2023, followed by France.
Aplastic Anemia Treatment Market Size is expected to increase due to several factors such as an increase in disease incidence in Asian countries, high patient uptake of PROMACTA (until expected patent expiry in 2025), approval of Teva Pharma’s ALVAIZ in the US, and Kyowa Kirin’s ROMIPLATE in Japan along with the expected launch of potential emerging therapies.
The leading Aplastic Anemia Companies such as Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.
Promising Aplastic Anemia Pipeline Therapies such as PF-06462700, REGN7257, BL-8040, and Others.

Stay ahead in the Aplastic Anemia Therapeutics Market with DelveInsight’s Strategic Report @ Aplastic Anemia Treatment Market

Aplastic Anemia Epidemiology Segmentation in the 7MM

Aplastic Anemia Incident Cases
Aplastic Anemia Severity-specific Cases
Aplastic Anemia Age-specific Cases

Download the report to understand which factors are driving Aplastic Anemia Epidemiology trends @ Aplastic Anemia Prevalence

Aplastic Anemia Marketed Therapies

ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

ALVAIZ (eltrombopag choline) is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. Lowest dose of ALVAIZ is use to achieve and maintain a hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 108 mg, and may take up to 16 weeks after starting ALVAIZ.

ROMIPLATE (romiplostim; AMG531): Kyowa Kirin/Amgen

ROMIPLATE is composed of recombinant protein acting on the thrombopoietin receptor, which has been licensed from Amgen (K-A) to Kyowa Kirin. It was launched as a drug for idiopathic thrombocytopenic purpura (ITP) in April 2011 and for aplastic anemia in patients who had an inadequate response to conventional therapy in June 2019 in Japan. The drug is composed of recombinant protein stimulating hematopoiesis via acting on the thrombopoietin receptors; Acts directly on megakaryocytic progenitor cells and exerts platelet hematopoietic effects. In addition, this drug promotes the proliferation and differentiation of megakaryocytic progenitor cells by binding to and activating thrombopoietin receptors.

Aplastic Anemia Emerging Therapies

REGN7257: Regeneron Pharmaceuticals

It’s a gc cytokine receptor antibody that targets the common g chain (gc; IL-2RG) found in interleukin (IL) receptors for various gc cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It was developed to investigate the potential of targeting gc cytokines for the prevention and treatment of T-cell-mediated diseases. By blocking the signaling of GC cytokines, REGN7257 aims to ameliorate T-cell-mediated pathogenesis. This antibody offers a promising approach to understand better the role of gc cytokines in inflammatory and autoimmune disease settings, where the lack of appropriate neutralizing antibodies recognizing IL-2RG has been a challenge.

OMISIRGE (omidubicel): Gamida Cell

OMISIRGE is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. It is indicated for use in adults and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection in this patient population. Omisirge has received approval for use in hematological malignancies and is currently undergoing evaluation in an ongoing investigator-sponsored Phase I/II study focusing on patients with severe aplastic anemia.

To learn more about Aplastic Anemia Treatment guidelines, visit @ Aplastic Anemia Clinical Trials Assessment

Aplastic Anemia Companies

Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.

Aplastic Anemia Market Outlook

The Aplastic Anemia Prognosis, varies based on the severity of the condition. Some cases can be successfully treated, while others may progress to severe complications, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically, the primary modalities for treating aplastic anemia have been IST and BMT in eligible patients. For individuals with SAA/VSAA deemed suitable for transplant-based interventions, age emerges as a pivotal determinant influencing survival post-matched sibling donor (MSD) allogeneic transplantation. Notably, older patients, often having undergone prior IST, presenting with additional comorbidities, diminished performance status, and an extended duration between diagnosis and BMT, exhibit distinctive challenges in outcomes, with fludarabine-containing regimens offering more promising results in this demographic, albeit based on limited retrospective analyses.

Aplastic Anemia Treatment Market

Because newly authorized Aplastic Anemia drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

Learn more about the FDA-approved drugs for Aplastic Anemia @ Drugs for Aplastic Anemia Treatment

Scope of the Aplastic Anemia Market Report

Coverage- 7MM
Study Period- 2020-2034
Aplastic Anemia Companies- Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.
Aplastic Anemia Pipeline Therapies- PF-06462700, REGN7257, BL-8040, and Others.
Aplastic Anemia Market Dynamics: Aplastic Anemia Market Drivers and Barriers
Aplastic Anemia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Aplastic Anemia

4. Aplastic Anemia Market Overview at a Glance

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 Disease Background and Overview

8 Treatment and Management of Aplastic Anemia

9 Epidemiology and Patient Population

10 Patient Journey

11 Aplastic Anemia Marketed Therapies

12 Aplastic Anemia Emerging Drugs

13 Aplastic Anemia: Market Analysis

14 Aplastic Anemia Unmet Needs

15 Aplastic Anemia SWOT Analysis

16 Aplastic Anemia KOL Views

17 Aplastic Anemia Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aplastic Anemia Treatment Market Size in the 7MM was ~USD 270 million in 2023 and is further expected to increase by 2034, estimates DelveInsight

Advanced Renal Cell Carcinoma Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “ Advanced Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of advanced renal cell carcinoma, historical and forecasted epidemiology as well as the advanced renal cell carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Advanced Renal Cell Carcinoma Market Share @ Advanced Renal Cell Carcinoma Market Outlook

Key Takeaways from the Advanced Renal Cell Carcinoma Market Report

In June 2025, Karie Runcie announced a study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
In June 2025, Bristol-Myers Squibb announced a study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
According to findings, renal cell carcinoma accounts for 90% of all kidney cancers.
One in three people with renal cell carcinoma receive a diagnosis at the metastatic stage.
RCC predominantly affects the male population, with men being significantly more susceptible as compared to women.
There are several types of RCC, but 75% of patients have a type called clear cell.
Several factors can be attributed to an increased risk of RCC, including smoking, obesity, and high blood pressure and having a family history of certain conditions, such as von Hippel-Lindau disease, a rare genetic multi-system disorder characterized by abnormal blood vessel growth.
RCC is difficult to detect in its early stages, and >30% patients with RCC have metastatic, or advanced, cancer at the time of diagnosis, meaning the cancer cells have spread beyond the kidney to other parts of the body.
The leading Advanced Renal Cell Carcinoma Companies such as CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.
Promising Advanced Renal Cell Carcinoma Pipeline Therapies such as Bevacizumab, Atezolizumab, TQB2450, Anlotinib, Sunitinib, HB0025, Botensilimab, Balstilimab, Ipilimumab and others.

Stay ahead in the Advanced Renal Cell Carcinoma Therapeutics Market with DelveInsight’s Strategic Report @ Advanced Renal Cell Carcinoma Treatment Market

Advanced Renal Cell Carcinoma Epidemiology Segmentation in the 7MM

Advanced Renal Cell Carcinoma Incident Cases of Kidney Cancer
Advanced Renal Cell Carcinoma Incident Cases
Advanced Renal Cell Carcinoma Subtype-specific Incident
Advanced Renal Cell Carcinoma Stage-specific Incident Cases
Advanced Renal Cell Carcinoma Gender-specific Incident Cases
Advanced Renal Cell Carcinoma Diagnosed and Treated Cases

Download the report to understand which factors are driving Advanced Renal Cell Carcinoma Epidemiology trends @ Advanced Renal Cell Carcinoma Prevalence

Marketed Advanced Renal Cell Carcinoma Drugs

KEYTRUDA (pembrolizumab): Merck

It is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. In April 2019, the FDA approved pembrolizumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma

WELIREG (belzutifan): Merck

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2α is targeted for ubiquitin-proteasomal degradation by VHL protein. In December 2023, the US FDA WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma.

Emerging Advanced Renal Cell Carcinoma Drugs

Zanzalintinib (XL092) + Nivolumab: Exelixis/BMS

Zanzalintinib represents a next‐generation oral TKI designed to inhibit the activity of receptor tyrosine kinases associated with cancer growth and spread. These include VEGF receptors, MET, AXL, and MER, which play crucial roles in various cellular functions and pathological processes such as oncogenesis, metastasis, and tumor angiogenesis. Zanzalintinib builds upon Exelixis’ extensive experience with cabozantinib, their flagship medicine, aiming to enhance key characteristics like pharmacokinetic half‐life.

Savolitinib + Durvalumab: AstraZeneca/HUTCHMED

Savolitinib is an investigational inhibitor of the mesenchymal–epithelial transition factor, or MET receptor tyrosine kinase, an enzyme that has been shown to function abnormally in many types of solid tumors. We designed savolitinib through chemical structure modification to specifically address kidney toxicity, the primary issue that halted the development of several other selective MET inhibitors

To learn more about Advanced Renal Cell Carcinoma Treatment guidelines, visit @ Advanced Renal Cell Carcinoma Clinical Trials Assessment

Advanced Renal Cell Carcinoma Companies

CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.

Advanced Renal Cell Carcinoma Market Outlook

Advanced Renal Cell Carcinoma companies, including Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED, are actively evaluating their lead candidates at various stages of clinical development, focusing on the treatment of advanced renal cell carcinoma. The Advanced Renal Cell Carcinoma market outlook appears promising, driven by these companies’ efforts to innovate and expand the therapeutic arsenal. As these investigational therapies progress through clinical trials, they hold the potential to significantly improve patient outcomes and address unmet needs in advanced renal cell carcinoma management. The competitive landscape is poised for dynamic growth, with advancements in targeted therapies, immunotherapies, and combination treatments, ultimately aiming to enhance survival rates and quality of life for patients.

Learn more about the FDA-approved drugs for Advanced Renal Cell Carcinoma @ Drugs for Advanced Renal Cell Carcinoma Treatment

Scope of the Advanced Renal Cell Carcinoma Market Report

Coverage- 7MM
Study Period- 2020-2034
Advanced Renal Cell Carcinoma Companies- CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.
Advanced Renal Cell Carcinoma Pipeline Therapies- Bevacizumab, Atezolizumab, TQB2450, Anlotinib, Sunitinib, HB0025, Botensilimab, Balstilimab, Ipilimumab and others.
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma Market Drivers and Barriers
Advanced Renal Cell Carcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Advanced Renal Cell Carcinoma (RCC)

4. Key Events

5. Advanced Renal Cell Carcinoma Epidemiology and Market Forecast Methodology

6. Advanced Renal Cell Carcinoma Market Overview at a Glance

7. Disease Background and Overview: RCC

8. Advanced Renal Cell Carcinoma Treatment and Management

9. Epidemiology and Patient Population of RCC in Latin America and Canada

10. Advanced Renal Cell Carcinoma Patient Journey

11. Key Endpoints in Advanced RCC

12. Marketed Advanced Renal Cell Carcinoma Therapies

13. Emerging Advanced Renal Cell Carcinoma Therapies

14. Advanced RCC: the US, EU4& the UK and Japan

15. Advanced Renal Cell Carcinoma Unmet Needs

16. Advanced Renal Cell Carcinoma SWOT Analysis

17. Advanced Renal Cell Carcinoma KOL Views

18. Advanced Renal Cell Carcinoma Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Renal Cell Carcinoma Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Vision Marine Secures U.S. Battery Supply Chain Through Strategic Expansion with Octillion Power Systems

U.S.-Assembled 45.36 kWh High-Voltage Packs from Nevada Facility to Promote Accelerated OEM and Consumer Growth Through E-Motion™ Platform

MONTREAL, QC – June 11, 2025 – Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a pioneer in high-voltage electric marine propulsion systems, today announced a major milestone in its U.S. scale-up strategy: the expansion of its longstanding partnership with Octillion Power Systems, a top-tier U.S.-based lithium-ion battery manufacturer, to produce Vision-branded high-voltage battery packs dedicated exclusively to the American market.

Under the terms of the agreement, Octillion will assemble Vision Marine’s new proprietary 45.36 kWh battery packs at its state-of-the-art facility in Nevada, aiding in fast, cost-efficient distribution across North America. These batteries are designed to support both Vision Marine’s OEM integrations and consumer-facing electric boat offerings, delivering increased power, extended range, and improved performance-while reducing total system cost and simplifying logistics.

This renewed and enhanced partnership establishes a partial U.S. supply chain for Vision Marine’s proprietary E-Motion™ 180E electric outboard system, unlocking key efficiencies. In addition to supporting factory integration with third-party manufacturers, the partnership provides a reliable and consistent battery supply for Vision Marine’s direct-to-consumer electric boat sales, including those produced under formal production agreements with multiple established boat manufacturers. These vessels are sold through Vision Marine’s channels while retaining the original manufacturer’s branding, enabling broad market reach without altering brand identity.

“Octillion has been an integral technology partner to Vision Marine for several years, powering our most high-performance programs-including multiple electric world speed record boats,” said Alexandre Mongeon, CEO of Vision Marine Technologies. “With this expanded partnership and the support of Octillion’s Nevada facility, we are positioned to scale commercial deliveries and prepare for our next record-setting performance with more power and higher efficiency.”

Founded in 2009 and headquartered in California, Octillion Power Systems is a global leader in lithium-ion battery technology, with over 2 million battery systems deployed across electric vehicles, industrial equipment, and energy storage sectors. Octillion brings deep technical expertise and proven large-scale manufacturing capabilities-essential components to Vision Marine’s growth roadmap.

“Having collaborated with Vision Marine since 2021 on the development of this American-built, marine-dedicated battery platform has been both technically rewarding and strategically significant,” said Paul Beach, President of Octillion Power Systems. “We are proud to manufacture these 45.36 kWh packs at our Nevada facility and to work in close alignment with Vision Marine’s team as they scale delivery and continue to push the boundaries of electric propulsion on water.”

In addition to supporting near-term production, Octillion’s close proximity and embedded technical collaboration introduce a new phase in Vision Marine’s development strategy. By aligning with a team that has delivered over 2 million battery systems globally, Vision Marine is now embracing a more agile, partner-integrated model of innovation, leveraging Octillion’s energy systems expertise to guide refinements and influence the evolution of future battery architectures.

The battery systems being manufactured by Octillion are integrated with Vision Marine’s patent-pending proprietary high-voltage marine propulsion powertrain -the first battery pack purpose-built for electric marine propulsion. Engineered to meet the demanding conditions of marine use, these packs deliver enhanced energy density, ruggedness, and integration simplicity-promoting optimal performance across a wide range of recreational and commercial applications.

The packs will be available exclusively with the E-Motion™ 180E outboard and offered as part of a fully integrated, plug-and-play powertrain solution. Designed for rapid OEM adoption and simplified factory installation, this system addresses long-standing industry barriers to electric adoption-namely cost, complexity, and limited performance.

By leveraging Octillion’s Nevada-based production infrastructure and forward-leaning technical engagement, Vision Marine becomes the first company in North America offering a fully industrialized, high-voltage electric marine outboard system with a U.S.-sourced battery solution -positioning the Company to meet growing demand for electrified boating while supporting regulatory and content compliance initiatives.

With domestic battery sourcing secured, enhanced pack performance, and ongoing collaboration with Octillion’s technical team, Vision Marine enters the second half of 2025 with the foundation to scale its go-to-market operations and accelerate its innovation agenda. As the Company advances, it remains committed to shaping the future of marine electrification by embracing cross-functional partnerships and leading-edge development models to bring next-generation technologies to the water.

About Octillion Power Systems

Octillion Power Systems is a U.S.-based global provider of advanced lithium-ion battery solutions for electric mobility and stationary energy storage. With over 2 million battery packs shipped worldwide, Octillion specializes in scalable, safe, and high-performance battery packs for transportation, industrial, and grid-connected applications. Visit www.octillion.us to learn more.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a pioneer in marine electrification. Its flagship E-Motion™ 180E system is a fully integrated high-voltage electric outboard powertrain built for OEM adoption at scale. Vision Marine designs and manufactures electric propulsion systems and boats to transform recreational and commercial boating into a zero-emission experience. Learn more at www.visionmarinetechnologies.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These statements include, but are not limited to, expectations regarding the benefits of the new patent, its impact on future product development and original equipment manufacturer integrations, and Vision Marine’s competitive position. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect results are discussed in the Company’s filings with the Securities and Exchange Commission. Vision Marine undertakes no obligation to update any forward-looking statements except as required by law.

Investor & Company Contact

Vision Marine Technologies

Bruce Nurse – Investor Relations

(303) 919-2913

bn@v-mti.com

Website: visionmarinetechnologies.com

Twitter: @marine_vision

Facebook: @VisionMarineTechnologies

Instagram: @visionmarine.technologies

YouTube: @VisionMarineTechnologies

Media Contact
Company Name: Microcap Headlines, Inc.
Contact Person: Natalie Peccia
Email: Send Email
Phone: (888) 254-2227
Country: United States
Website: http://www.microcapheadlines.com/